Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials

IMPORTANCE: Phase 2 trials and early efficacy end points play a crucial role in informing decisions about whether to continue to phase 3 trials. Conventional end points, such as objective response rate (ORR) and progression-free survival (PFS), have demonstrated inconsistent associations with overal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Netw Open
Autors principals: Hu, Chen, Wang, Meihua, Wu, Cai, Zhou, Heng, Chen, Cong, Diede, Scott
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2021
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8164100/
https://ncbi.nlm.nih.gov/pubmed/34047794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2021.8175
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars